 The test is specific for heterophile antibodies produced by the human immune system in response to EBV infection.Commercially available test kits are 70–92% sensitive and 96–100% specific, with a lower sensitivity in the first two weeks after clinical symptoms begin.The United States Center for Disease Control deems the monospot test to not be very useful.